Patents by Inventor Hiroki Shirai
Hiroki Shirai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250085370Abstract: An MRI apparatus includes a measurement point determination unit that determines each measurement point of three-dimensional k-space data. In a case where a kx direction of a three-dimensional k-space is set as a readout direction, for a plurality of measurement points on a ky-kz plane, the measurement point determination unit adjusts a first condition that an angle of a straight line connecting the measurement points and a center of the plane changes with a golden angle (?) and a distance (r) from a center point of the plane monotonically increases, and determines the measurement point to satisfy a second condition that a change in a position of the measurement point is to be non-periodicity.Type: ApplicationFiled: September 3, 2024Publication date: March 13, 2025Inventors: Tomoki Amemiya, Atsuro Suzuki, Yukio Kaneko, Suguru Yokosawa, Toru Shirai, Hiroki Shoji
-
Patent number: 12240362Abstract: A seat cushion frame configuring framework of a seat cushion for an occupant of a vehicle to sit on, and including left and right side frames, a cushion pan, and a reinforcement member. The left and right side frames are disposed at left and right side portions of the seat cushion. The cushion pan connects upper end portions of front portions of the left and right side frames together in a seat left-right direction. The reinforcement member includes the left and right reinforcement portions respective affixed to the seat left-right direction sides of the rear end portion of the cushion pan.Type: GrantFiled: December 22, 2022Date of Patent: March 4, 2025Assignees: NHK Spring Co., Ltd., Subaru CorporationInventors: Syunichirou Osa, Hiroki Matsuda, Jun Shirai, Masafumi Takano, Fumito Kitanaka, Kenji Nagumo, Suguru Ishikawa
-
Patent number: 12227586Abstract: An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon ? by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.Type: GrantFiled: April 21, 2022Date of Patent: February 18, 2025Assignees: Astellas Pharma Inc., National Cancer CenterInventors: Yoshiyuki Tenda, Masatoshi Yuri, Shigenori Yagi, Yoshiki Satake, Kazunori Hirayama, Hiroki Shirai, Hiroki Sasaki, Fumiko Chiwaki, Masayuki Komatsu
-
Patent number: 12202908Abstract: Provided are a conjugate comprising an anti-human MUC1 antibody Fab fragment and a peptide linker and/or a ligand, a composition for diagnosis and/or a pharmaceutical composition comprising the conjugate, a method for diagnosing and/or treating a cancer using the conjugate, and the like. In the conjugate used, the anti-human MUC1 antibody Fab fragment is bound to the ligand via the peptide linker or the like.Type: GrantFiled: May 17, 2019Date of Patent: January 21, 2025Assignee: Astellas Pharma Inc.Inventors: Toru Asano, Yorikata Sano, Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Michinori Akaiwa, Hiroyoshi Yamada, Nobuyuki Shiraishi
-
Publication number: 20240209108Abstract: An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon ? by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.Type: ApplicationFiled: April 21, 2022Publication date: June 27, 2024Applicants: Astellas Pharma Inc., National Cancer CenterInventors: Yoshiyuki TENDA, Masatoshi YURI, Shigenori YAGI, Yoshiki SATAKE, Kazunori HIRAYAMA, Hiroki SHIRAI, Hiroki SASAKI, Fumiko CHIWAKI, Masayuki KOMATSU
-
Publication number: 20230303658Abstract: The present invention provides a polypeptide comprising a modified Fc region of an IgG, and a modified Fcy receptor that binds specifically to the polypeptide, and methods for treating or preventing a disease or a disorder in a patient using immunotherapy.Type: ApplicationFiled: August 18, 2021Publication date: September 28, 2023Inventors: Ryuichi Moriya, Hiroki Shirai, Shinji Soga, Naoko Shimada, David William Russell
-
Patent number: 11679166Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.Type: GrantFiled: November 12, 2019Date of Patent: June 20, 2023Assignee: Astellas Pharma Inc.Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
-
Patent number: 11667724Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.Type: GrantFiled: July 6, 2018Date of Patent: June 6, 2023Assignee: ASTELLAS PHARMA INC.Inventors: Hitoshi Doihara, Kazunori Hirayama, Hiroki Shirai
-
Publication number: 20220096653Abstract: Provided is a conjugate comprising a ligand, a spacer, and a peptide linker useful for an in-vivo diagnostic drug and internal radiation therapy, using an anti-human CEACAM5 antibody Fab fragment whose binding activity is not attenuated even by labeling with a metal, a fluorescent dye, or the like. A conjugate comprising an anti-human CEACAM5 antibody Fab fragment and a ligand, the fragment comprising a heavy chain fragment including a heavy chain variable region consisting of a specific amino acid sequence and a light chain including a light chain variable region consisting of a specific amino acid sequence, or a conjugate comprising a ligand, a spacer, and a peptide linker, wherein the binding activity thereof is not attenuated even by labeling with a metal, a fluorescent dye, or the like, can be used as a diagnostic composition and/or a pharmaceutical composition.Type: ApplicationFiled: January 6, 2020Publication date: March 31, 2022Inventors: Michinori Akaiwa, Junya Ishida, Hiroki Toya, Nobuyuki Shiraishi, Toru Asano, Tomoaki Yoshikawa, Yorikata Sano, Hitoshi Doihara, Hiroki Shirai, Kazunori Hirayama
-
Publication number: 20210340276Abstract: Provided are a conjugate comprising an anti-human MUC1 antibody Fab fragment and a peptide linker and/or a ligand, a composition for diagnosis and/or a pharmaceutical composition comprising the conjugate, a method for diagnosing and/or treating a cancer using the conjugate, and the like. In the conjugate used, the anti-human MUC1 antibody Fab fragment is bound to the ligand via the peptide linker or the like.Type: ApplicationFiled: May 17, 2019Publication date: November 4, 2021Applicant: Astellas Pharma Inc.Inventors: Toru ASANO, Yorikata SANO, Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Michinori AKAIWA, Hiroyoshi YAMADA, Nobuyuki SHIRAISHI
-
Publication number: 20200261603Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.Type: ApplicationFiled: November 12, 2019Publication date: August 20, 2020Applicant: Astellas Pharma Inc.Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
-
Publication number: 20200171174Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.Type: ApplicationFiled: November 14, 2019Publication date: June 4, 2020Applicant: Astellas Pharma Inc.Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
-
Publication number: 20200123270Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.Type: ApplicationFiled: July 6, 2018Publication date: April 23, 2020Inventors: Hitoshi Doihara, Kazunori Hirayama, Hiroki Shirai
-
Patent number: 10517966Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.Type: GrantFiled: November 17, 2017Date of Patent: December 31, 2019Assignee: Astellas Pharma Inc.Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
-
Patent number: 10507251Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.Type: GrantFiled: May 17, 2019Date of Patent: December 17, 2019Assignee: Astellas Pharma Inc.Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
-
Publication number: 20190307906Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.Type: ApplicationFiled: November 17, 2017Publication date: October 10, 2019Applicant: Astellas Pharma Inc.Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
-
Publication number: 20190269804Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.Type: ApplicationFiled: May 17, 2019Publication date: September 5, 2019Applicant: Astellas Pharma Inc.Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
-
Patent number: 8946800Abstract: To provide a semiconductor device featuring reduced variation in capacitor characteristics. In the semiconductor device, a protective layer is provided at the periphery of the upper end portion of a recess (hole). This protective layer has a dielectric constant higher than that of an insulating layer placed in the same layer as the protective layer and configuring a multilayer wiring layer placed in a logic circuit region.Type: GrantFiled: August 23, 2012Date of Patent: February 3, 2015Assignee: Renesas Electronics CorporationInventors: Ippei Kume, Kenichiro Hijioka, Naoya Inoue, Hiroyuki Kunishima, Manabu Iguchi, Hiroki Shirai
-
Patent number: 8648441Abstract: A semiconductor device has a substrate; a multi-layered interconnect formed on the substrate, and having a plurality of interconnect layers, each of which being configured by an interconnect and an insulating layer, stacked therein; a memory circuit formed in a memory circuit region on the substrate in a plan view, and having a peripheral circuit and at least one capacitor element embedded in the multi-layered interconnect; and a logic circuit formed in a logic circuit region on the substrate, wherein the capacitor element is configured by a lower electrode, a capacitor insulating film, an upper electrode, an embedded electrode and an upper interconnect; the top surface of the upper interconnect, and the top surface of the interconnect configuring the logic circuit formed in the same interconnect layer with the upper interconnect, are aligned to the same plane.Type: GrantFiled: May 12, 2011Date of Patent: February 11, 2014Assignee: Renesas Electronics CorporationInventors: Kenichiro Hijioka, Ippei Kume, Naoya Inoue, Hiroki Shirai, Jun Kawahara, Yoshihiro Hayashi
-
Patent number: D1065479Type: GrantFiled: December 2, 2021Date of Patent: March 4, 2025Assignee: Mitsubishi Electric CorporationInventors: Shoichi Hirano, Kenshiro Kawabata, Shota Shirai, Yuji Tarumi, Yuji Motomura, Ryosuke Matsui, Hiroki Washiyama